Abstract 500P
Background
Despite extensive studies of the impact of COVID-19 on patients with cancer, there is a dearth of information from the MENA region. Our study aims to report pertinent MCCR findings on patient management and outcomes.
Methods
MCCR was adapted from ASCO COVID-19 Registry to collect data on patients with cancer and SARS-CoV-2 infection from 12 centers in eight countries including: Saudi Arabia, Jordan, Lebanon, Turkey, Egypt, Algeria, United Arab Emirates, and Morocco. The Registry included data on patients and disease characteristics, treatment, and patient outcomes.
Results
Between November 29, 2020 and December 7, 2021, data on 1345 patients were captured. Median age was 57 years (18-98), 56.1% females, and 27.1% were current or ex-smokers. Out of the 1144 patients (85.1%) with solid tumors, delays of planned treatment > 14 days occurred in 81.4% for surgery, 51.7% for radiation therapy and 34.6% for drug therapy. No delays in surgery and radiation therapy occurred after June 1, 2020, and the delays of drug therapy were reduced from 20.8% to 5.2% (P < 0.0001). All-cause mortality at 30 and 90 days were 15.9% and 22.1%, respectively. All-cause mortality rates at 30 and 90 days were reduced after June 1st, 2020, from 17.3% to 3.7%, and from 24.2% to 3.7%, respectively (P < 0.0001). Univariate analysis showed multiple prognotic factors such as age > 70 years, male gender, lung cancer vs other solid tumors, diagnosis of COVID-19 before June 2020, ever smokers, among others. The Multivariate Logistic Regression analysis results shown in Table. Table: 500P
Multivariate logistic regression analysis of 30- and 90-days all-cause mortality (N=1345 patients)
| 30 Days All-Cause Mortality | 90 Days All-Cause Mortality | |||||
| OR | 95% CI | P-value | OR | 95% CI | P-value | |
| Diagnosed after June 1, 2020 vs. before June 1, 2020* | 0.251 | 0.095-0.663 | 0.005 | 0.125 | 0.047-0.328 | <0.0001 |
| On chemotherapy at diagnosis yes vs. no* | 0.645 | 0.398-1.045 | 0.075 | 0.642 | 0.411-1.000 | 0.050 |
| Stable Disease vs. Progressing disease* | 0.244 | 0.132-0.451 | <0.0001 | 0.185 | 0.108-0.319 | <0.0001 |
| Metastatic vs. Locoregional disease* | 2.408 | 1.222-4.748 | 0.011 | 3.313 | 1.783-6.156 | <0.0001 |
| Comorbidities vs. no comorbidity* | 1.732 | 1.067-2.813 | 0.026 | 1.799 | 1.150-2.814 | 0.010 |
| Obesity vs. none* | 0.716 | 0.444-1.155 | 0.171 | 0.591 | 0.381-0.915 | 0.018 |
∗ Reference group.
Conclusions
Patients with cancer in MENA region experienced similar risks and outcome of COVID-19 reported in other populations. The reduction in mortality rate after June 2020 reflects a better approach to managing these patients resulting in improved outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.R. Jazieh.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.